Bone is not on the list of things TUDCA is sold for, which makes it one of the more interesting places to look. There is a real experimental literature here, most of it published since 2015, and almost all of it built on the same premise as the rest of this site: that osteoblasts are secretory cells, secretory cells depend on the endoplasmic reticulum, and relieving ER stress changes what those cells do.
What follows is entirely animal and cell work. No human bone trial of TUDCA has been published. That is stated once here rather than repeated at the end of every paragraph, and it is the single most important thing on this page.
Key Takeaways
- In ovariectomised mice, a model of postmenopausal bone loss, TUDCA preserved more trabecular structure in the distal femur and raised bone mineral density and bone volume fraction against vehicle[1].
- In that same study the serum bone formation marker PINP was higher and the resorption marker CTX was lower, but neither difference reached statistical significance[1]. The imaging moved and the blood chemistry did not.
- TUDCA pushed mesenchymal stem cells towards bone rather than fat, and improved healing of surgically created skull defects in rodents[2] and rabbits[3].
- Part of the effect appears not to be about bone cells at all. TUDCA increased migration and tube formation in human endothelial cells, and bone regeneration tracked the new blood supply[3].
- One study points the other way. In a cell model of ectopic ossification, where mineral forms in tissue that should not mineralise, TUDCA suppressed osteoblastic differentiation and mineralisation[4].
- Every dose here is either a concentration in a dish or an injection, and several of the bone defect studies applied TUDCA locally at the surgical site[2][3]. None of it describes a capsule.
Why Anyone Looked at Bone in the First Place
Osteoblasts build bone by secreting collagen, and a great deal of collagen. Cells with that kind of secretory load run their endoplasmic reticulum hard, and when the ER is overloaded the unfolded protein response can tip a cell from differentiation into apoptosis. That is the same logic behind TUDCA’s neuroprotection work and its apoptosis inhibition, applied to a different cell type.
There is a second, less obvious reason. Bone marrow mesenchymal stem cells can become either osteoblasts or adipocytes, and those two fates compete. A 2016 paper in Bone reports that the group had already found TUDCA reduces adipogenesis in these cells, then asked the obvious follow-up question: if less fat, then more bone?[2]
Both lines converge on the same prediction, which is why this literature exists at all. Whether the prediction survived contact with an animal is the rest of this page.
The Ovariectomy Study, Read Carefully
The most complete animal experiment is a 2020 paper in International Journal of Molecular Sciences that starts in a dish and finishes in a mouse[1]. In vitro, TUDCA at 100 nanomolar and 1 micromolar increased osteoblast proliferation, viability, differentiation and mineralisation, and it blunted osteoblast apoptosis caused by methylprednisolone, a corticosteroid that causes bone loss in people.
The animal arm used three groups of eight three-month-old female C57BL/6 mice: untouched controls, ovariectomy with vehicle, and ovariectomy with TUDCA given every other day for four weeks beginning six weeks after surgery. Note the timing, because it matters. Treatment started after bone loss was already underway, which is the clinically realistic version of the question.
At eleven weeks after surgery, micro-computed tomography and histology showed the TUDCA group had preserved more trabecular structure in the distal femur, with a higher percentage bone volume relative to total volume and higher bone mineral density than the vehicle group.
Then the part that most summaries leave out. The authors also measured two serum markers of bone turnover: PINP, which goes up when bone is being built, and CTX, which goes up when bone is being broken down. PINP was higher in the TUDCA group and CTX was lower, exactly the direction you would want, and neither difference was statistically significant against vehicle. So the structural imaging and the circulating chemistry disagree, and with eight animals per group there is not enough power to say which one is telling the truth.
A separate 2024 study in ovariectomised rats combined TUDCA with selenium and reported accelerated bone regeneration, with reduced intracellular and mitochondrial reactive oxygen species in osteoblast-like cells stressed with hydrogen peroxide[5]. It is supporting evidence for the antioxidant mechanism, but because it tests a combination it cannot tell you what TUDCA did on its own.
The Bone Defect Studies Are About Surgery, Not Supplements
Several of the strongest-looking results come from calvarial defect models, where a hole is made in a rodent or rabbit skull and healing is measured. TUDCA improved bone regeneration in a mouse calvarial model, confirmed by micro-CT, histology and osteocalcin staining, and the mechanism was traced to integrin alpha-5 and ERK1/2 signalling with reduced apoptosis and inflammation[2]. A 2023 paper in Cells found a parallel pathway in human mesenchymal stem cells, through EGFR, phosphorylated Akt and CREB1[6].
These are tissue engineering experiments. The question they answer is whether TUDCA is useful as a component of a graft or scaffold placed at a surgical site, which is a genuinely promising question and a completely different one from whether swallowing TUDCA helps a person with thinning bone.
The 2020 rabbit study makes the distinction sharper, and it is the most conceptually interesting paper in the set[3]. It started in human umbilical vein endothelial cells, not bone cells, and found TUDCA increased proliferation, migration and tube formation with phosphorylation of MAPK, AKT and endothelial nitric oxide synthase. Bone healing needs a blood supply, and in the rabbit calvarial model both new bone and new vessels increased. If a meaningful share of the bone effect is really an angiogenesis effect delivered locally, then systemic oral dosing is even less likely to reproduce it.
The Study That Points the Other Way
A 2015 paper used inorganic phosphate to drive NIH3T3 fibroblasts into osteogenesis and mineralisation as a model of ectopic ossification, the pathological formation of bone in soft tissue[4]. TUDCA, at 0.1 to 10 micromolar, attenuated that osteoblastic differentiation and mineralisation by inhibiting the ER stress response.
Read alongside the osteoporosis work, this is not a contradiction so much as a correction to how the mechanism gets described. TUDCA is not a bone builder. It is an ER stress inhibitor, and when ER stress is the thing driving mineral formation, inhibiting it produces less mineral, not more. The direction of the effect depends on the cell and on what is stressing it.
That should make anyone cautious about the confident one-line version of this literature. It also matters clinically for the same reason a 2025 finding in muscle matters: TUDCA increased ectopic calcification specifically in dystrophic mouse muscle, discussed on the muscle atrophy page. Mineral appearing where it should not is a recurring theme in this compound’s animal data, and it is not a theme the marketing mentions.
What Would Have to Be True for This to Matter in a Person
Three things, none of which is currently established. First, an oral dose would have to produce tissue concentrations in bone comparable to the nanomolar to micromolar range used in these dishes, and TUDCA’s absorption and distribution have not been characterised in bone at all. Second, the structural benefit seen on micro-CT would have to show up in a measure that predicts fractures in humans, and the two blood markers that might have supported it did not move significantly. Third, the effect would have to hold in a population on the drugs real patients take.
None of that makes the research uninteresting. Corticosteroid-induced bone loss is a common, poorly solved clinical problem, and the in vitro finding that TUDCA blunts methylprednisolone-induced osteoblast apoptosis[1] is a reasonable starting point for someone to test properly.
It is not a reason to take TUDCA for bone density. Osteoporosis has treatments with fracture endpoints from trials in tens of thousands of people, and a supplement with no human bone data is not an alternative to them. If you are taking TUDCA for liver reasons and wondering whether bone is a bonus, the honest answer is that nobody knows, and the ectopic mineralisation findings mean it is not safe to assume the surprise would be a pleasant one.
Nothing on this page is medical advice. Osteoporosis is diagnosed and treated by measuring bone density and fracture risk, and those decisions should not be made around a supplement.
Frequently Asked Questions
Does TUDCA increase bone density?
In ovariectomised mice it preserved trabecular structure and raised bone mineral density and bone volume fraction on micro-CT against vehicle[1]. In the same animals the serum markers PINP and CTX moved in the favourable direction but not significantly, with eight mice per group. No human study has measured bone density on TUDCA, so there is no answer for people.
Can TUDCA help steroid-induced bone loss?
Only in a dish so far. TUDCA reduced osteoblast apoptosis caused by methylprednisolone in vitro[1]. That is a sensible hypothesis and it has not been tested in an animal on a corticosteroid course, let alone in a patient. A prescribed steroid course should not be modified around a supplement, and corticosteroid bone loss has established prophylaxis worth asking a doctor about.
Why do some studies say TUDCA reduces mineralisation?
Because the direction depends on context. In a phosphate-driven model of ectopic ossification, TUDCA suppressed osteoblastic differentiation and mineralisation by inhibiting ER stress[4]. TUDCA is acting on ER stress rather than on bone formation as such, so where ER stress drives mineral deposition, blocking it yields less mineral. Framing TUDCA as a bone builder misreads the mechanism.
Do the skull defect studies apply to taking a capsule?
Not directly. Those studies create a bone defect surgically and assess healing, often with TUDCA applied locally[2][3], and a substantial part of the benefit tracked new blood vessel formation rather than osteoblast activity[3]. They speak to TUDCA as a graft or scaffold component in surgery, which is a different question from oral supplementation.
References
- Therapeutic Potential of Tauroursodeoxycholic Acid for the Treatment of Osteoporosis. Int J Mol Sci (2020).
- Administration of tauroursodeoxycholic acid enhances osteogenic differentiation of bone marrow-derived mesenchymal stem cells and bone regeneration. Bone (2016).
- Tauroursodeoxycholic acid induces angiogenic activity in endothelial cells and accelerates bone regeneration. Bone (2020).
- Tauroursodeoxycholic acid attenuates inorganic phosphate-induced osteoblastic differentiation and mineralization in NIH3T3 fibroblasts by inhibiting the ER stress response. Drug Discov Ther (2015).
- Tauroursodeoxycholic acid combined with selenium accelerates bone regeneration in ovariectomized rats. J Mater Sci Mater Med (2024).
- Tauroursodeoxycholic Acid Enhances Osteogenic Differentiation through EGFR/p-Akt/CREB1 Pathway in Mesenchymal Stem Cells. Cells (2023).
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
